Get started
MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT)MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT)MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT)

MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0K2H chart


Full chart

0K2H upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.14 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−11.70 USD
Net income (FY)
‪−29.77 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪2.90 M‬
Beta (1Y)
1.27

Employees


Employees (FY)
18
Change (1Y)
−1 −5.26%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.65 M‬ USD

About Moleculin Biotech, Inc.


Sector
Health Technology
CEO
Walter V. Klemp
Headquarters
Houston
Website
moleculin.com
FIGI
BBG00JVRFDT8
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0K2H news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0K2H is 3.00 USD — it has increased by 2.68% in the past 24 hours. Watch MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stocks are traded under the ticker 0K2H.
0K2H stock has risen by 22.29% compared to the previous week, the month change is a 22.29% rise, over the last year MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) has showed a −97.67% decrease.
We've gathered analysts' opinions on MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) future price: according to them, 0K2H price has a max estimate of 28.00 USD and a min estimate of 8.00 USD. Watch 0K2H chart and read a more detailed MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock forecast: see what analysts think of MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) and suggest that you do with its stocks.
0K2H reached its all-time high on Feb 16, 2018 with the price of 3,780.00 USD, and its all-time low was 2.28 USD and was reached on Aug 5, 2024. View more price dynamics on 0K2H chart.
See other stocks reaching their highest and lowest prices.
0K2H stock is 2.61% volatile and has beta coefficient of 1.27. Track MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) there?
Today MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) has the market capitalization of ‪7.56 M‬, it has increased by 21.13% over the last week.
Yes, you can track MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
0K2H earnings for the last quarter are −2.85 USD per share, whereas the estimation was −2.44 USD resulting in a −16.80% surprise. The estimated earnings for the next quarter are −1.26 USD per share. See more details about MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) earnings.
MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0K2H net income for the last quarter is ‪−10.59 M‬ USD, while the quarter before that showed ‪−4.32 M‬ USD of net income which accounts for −145.24% change. Track more MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) financial stats to get the full picture.
No, 0K2H doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 19, 2024, the company has 18.00 employees. See our rating of the largest employees — is MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) on this list?
Like other stocks, 0K2H shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock shows the sell signal. See more of MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.